← Back to Search

Dietary Supplement

Fiber Inulin for Chronic Obstructive Pulmonary Disease

N/A
Waitlist Available
Led By Marielle Engelen
Research Sponsored by Texas A&M University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No diagnosis of COPD
Ability to lie in supine or elevated position for 1.5 hours
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 1, 2, 4, and 5
Awards & highlights

Study Summary

This trial will compare changes in short chain fatty acid (SCFA) metabolism after inulin vs. placebo intake in COPD patients to healthy matched controls.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Aging

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You do not have a diagnosis of COPD (chronic obstructive pulmonary disease).
Select...
You can comfortably lie down flat or with your upper body elevated for 1.5 hours.
Select...
You have difficulty breathing when you do physical activities.
Select...
You have been feeling well and haven't had a respiratory infection or worsening of your condition for at least 4 weeks before the first test day.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intestinal microbiota composition by stool sample collection using Shallow Shotgun Sequencing
Whole body short-chain fatty acid production rates by plasma samples
Secondary outcome measures
3-day diet diary
6 minute walk test distance
Attention and executive functions measured by Stroop Color-Word Test (SCWT)
+19 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Healthy Young ParticipantsExperimental Treatment2 Interventions
healthy young subjects with age 18-30 years old
Group II: Healthy ParticipantsExperimental Treatment2 Interventions
healthy control subjects
Group III: Chronic Obstructive Pulmonary Disease patientsExperimental Treatment2 Interventions
Established diagnosis of Chronic Obstructive Pulmonary Disease

Find a Location

Who is running the clinical trial?

Texas A&M UniversityLead Sponsor
137 Previous Clinical Trials
23,282 Total Patients Enrolled
Marielle EngelenPrincipal InvestigatorTexas A&M University - CTRAL
4 Previous Clinical Trials
234 Total Patients Enrolled

Media Library

Inulin (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04459156 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: Chronic Obstructive Pulmonary Disease patients, Healthy Participants, Healthy Young Participants
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Inulin Highlights & Side Effects. Trial Name: NCT04459156 — N/A
Inulin (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04459156 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this research endeavor still open to the public?

"Correct. Information posted to clinicaltrials.gov confirms that this medical trial, first published on June 23rd 2020, is actively enrolling volunteers. Approximately 150 individuals are needed at 1 specified site for participation in the study."

Answered by AI

How many individuals have been recruited to participate in this research endeavor?

"Affirmative. Clinicaltrials.gov's records imply that this medical trial is presently seeking participants, with the initial posting dated June 23rd 2020 and the latest update on December 10th 2021. One location needs to fill 150 positions for this project."

Answered by AI

What are the key objectives of this trial?

"This trial, which will take place over a five-week period, intends to analyse intestinal microbiota composition by collecting stool samples with shallow shotgun sequencing. Secondary objectives include assessing state of mood through the Hospital Anxiety and Depression Scale (HADS), determining COPD impacts via self-administered questionnaire, and measuring bone mineral density through bioelectrical impedance analysis (BIA)."

Answered by AI
~32 spots leftby Mar 2025